CJC-1295 Acetate, a synthetic peptide analog of growth hormone-releasing hormone (GHRH), has garnered significant attention in the realm of peptide therapeutics. Its potential to stimulate growth hormone production and subsequent benefits have made it a subject of intense research. However, a crucial aspect of its efficacy lies in its stability under physiological conditions. This article delves into the stability of CJC-1295 Acetate in various physiological environments, exploring its behavior in bloodstream pH, thermal stability, and degradation rates compared to non-acetylated forms.
Product Code: BM-2-4-007
English Name: CJC-1295 Acetate
CAS No.: 863288-34-0
Molecular formula: C152H252N44O42
Molecular weight: 3367.89688
EINECS No.: 206-141-6
HS code: /
Analysis items: HPLC>99.0%, LC-MS
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand, Canada, etc.
Manufacturer: BLOOM TECH Changzhou Factory
Technology service: R&D Dept.-3
We provide CJC-1295 Acetate CAS 863288-34-0, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/synthetic-chemical/peptide/cjc-1295-acetate-cas-863288-34-0.html
How stable is CJC-1295 Acetate in bloodstream pH?
The stability of CJC-1295 Acetate in the bloodstream pH is a critical factor determining its therapeutic efficacy. The human bloodstream typically maintains a pH range of 7.35 to 7.45, which is slightly alkaline. In this environment, CJC-1295 Acetate exhibits remarkable stability, primarily due to its acetylation.
Acetylation, the process of adding an acetyl group to the peptide, enhances its resistance to enzymatic degradation. This modification significantly prolongs the half-life of CJC-1295 in the bloodstream, allowing it to circulate for extended periods without losing its biological activity.
Research has shown that CJC-1295 Acetate maintains its structural integrity and functional properties in bloodstream pH for up to several days. This prolonged stability is a significant advantage over non-acetylated peptides, which often degrade rapidly in physiological conditions.
The stability of CJC-1295 Acetate in bloodstream pH is attributed to several factors:
- Resistance to Proteolytic Enzymes: The acetyl group protects the peptide from rapid breakdown by proteolytic enzymes present in the blood.
- Reduced Renal Clearance: Acetylation increases the molecular weight of the peptide, reducing its renal clearance rate and prolonging its circulation time.
- Enhanced Binding to Plasma Proteins: CJC-1295 Acetate exhibits improved binding to plasma proteins, which further contributes to its extended half-life in the bloodstream.
These factors collectively contribute to the superior stability of CJC-1295 Acetate in physiological pH conditions, making it an attractive candidate for therapeutic applications requiring sustained peptide activity.
Thermal stability of CJC-1295 Acetate solutions
The thermal stability of CJC-1295 Acetate solutions is another crucial aspect to consider, especially in the context of storage, transportation, and administration. Peptides are generally sensitive to temperature fluctuations, which can lead to degradation and loss of biological activity. However, CJC-1295 Acetate demonstrates commendable thermal stability compared to many other peptides.
Studies have shown that CJC-1295 Acetate remains stable at room temperature (20-25°C) for extended periods, typically up to several weeks. This stability is particularly advantageous for practical applications, as it reduces the need for stringent cold-chain logistics during transportation and storage.
The thermal stability of CJC-1295 Acetate solutions can be attributed to several factors:
- Acetylation: The acetyl group not only enhances resistance to enzymatic degradation but also provides some protection against thermal denaturation.
- Molecular Structure: The specific amino acid sequence and three-dimensional structure of CJC-1295 contribute to its thermal stability.
- Formulation Techniques: Advanced formulation techniques, such as lyophilization (freeze-drying), can further enhance the thermal stability of CJC-1295 Acetate solutions.
While CJC-1295 Acetate demonstrates good thermal stability at room temperature, it's important to note that prolonged exposure to high temperatures should still be avoided. For optimal stability and potency, it's recommended to store CJC-1295 Acetate solutions refrigerated (2-8°C) when not in use.
The thermal stability profile of CJC-1295 Acetate solutions has been studied under various conditions:
- Short-term Exposure: Brief exposure to temperatures up to 37°C (body temperature) does not significantly affect the stability or activity of CJC-1295 Acetate.
- Long-term Storage: When stored at 2-8°C, CJC-1295 Acetate solutions maintain their stability and potency for several months.
- Freeze-Thaw Cycles: CJC-1295 Acetate has shown resistance to multiple freeze-thaw cycles, which is beneficial for laboratory research and clinical applications.
The thermal stability of CJC-1295 Acetate solutions underscores its potential as a robust therapeutic peptide, capable of withstanding various environmental conditions without compromising its efficacy.
|
|
|
CJC-1295 Acetate vs non-acetylated forms: Degradation rates
A comparative analysis of degradation rates between CJC-1295 Acetate and its non-acetylated counterparts reveals significant differences in stability and longevity. This comparison is crucial for understanding the advantages of acetylation in peptide therapeutics.
CJC-1295 Acetate exhibits markedly slower degradation rates compared to non-acetylated forms of growth hormone-releasing hormone (GHRH) analogs. The acetylation process confers several stability-enhancing properties:
- Extended Half-life: CJC-1295 Acetate boasts a half-life of several days, compared to the mere minutes or hours of non-acetylated GHRH analogs.
- Reduced Enzymatic Degradation: The acetyl group provides steric hindrance, protecting the peptide from rapid enzymatic breakdown.
- Improved Pharmacokinetics: Slower degradation translates to more consistent plasma levels and prolonged biological activity.
The degradation rates of CJC-1295 Acetate and non-acetylated forms have been studied in various physiological conditions:
- In Vitro Studies: Laboratory experiments simulating physiological conditions have shown that CJC-1295 Acetate retains over 90% of its initial concentration after 24 hours, while non-acetylated forms may degrade by 50% or more in the same timeframe.
- In Vivo Studies: Animal and human studies have demonstrated that CJC-1295 Acetate maintains detectable and biologically active levels in the bloodstream for up to 6-8 days post-administration. In contrast, non-acetylated GHRH analogs are typically cleared from the system within hours.
- Tissue Distribution: CJC-1295 Acetate shows improved tissue penetration and longer residence time in target tissues compared to non-acetylated forms, further contributing to its prolonged effects.
The slower degradation rate of CJC-1295 Acetate offers several advantages in therapeutic applications:
- Reduced Dosing Frequency: The extended half-life allows for less frequent administration, improving patient compliance and convenience.
- More Consistent Effects: Slower degradation results in more stable plasma levels, potentially leading to more consistent therapeutic outcomes.
- Improved Safety Profile: Lower peak concentrations and more gradual elimination may contribute to a reduced risk of side effects compared to rapidly degrading non-acetylated forms.
It's worth noting that while acetylation significantly enhances the stability of CJC-1295, it does not render the peptide completely immune to degradation. Factors such as temperature, pH, and the presence of specific enzymes can still influence its degradation rate, albeit to a lesser extent than non-acetylated forms.
The superior stability of CJC-1295 Acetate compared to non-acetylated forms underscores its potential as a more effective and user-friendly therapeutic option. However, it's crucial to consider that the choice between acetylated and non-acetylated peptides may depend on the specific therapeutic goals, target tissues, and desired pharmacokinetic profile.
In conclusion, the stability of CJC-1295 Acetate in physiological conditions is a testament to the power of strategic chemical modifications in enhancing peptide therapeutics. Its remarkable stability in bloodstream pH, thermal resilience, and significantly slower degradation rates compared to non-acetylated forms make it a promising candidate for various therapeutic applications.
The enhanced stability of CJC-1295 Acetate not only improves its potential efficacy but also offers practical advantages in terms of storage, administration, and patient compliance. As research in peptide therapeutics continues to advance, the lessons learned from CJC-1295 Acetate's stability profile may pave the way for the development of even more stable and effective peptide-based treatments.
For pharmaceutical companies and research institutions looking to explore the potential of CJC-1295 Acetate or similar peptide therapeutics, partnering with a reliable supplier is crucial. Shaanxi BLOOM TECH Co., Ltd., established in 2009, offers high-quality peptide products manufactured in GMP-certified facilities. With expertise in various reaction and purification techniques, BLOOM TECH is well-equipped to meet the demanding requirements of peptide synthesis and production.
If you're interested in learning more about CJC-1295 Acetate or other peptide products for pharmaceutical research, don't hesitate to reach out. Contact our team at Sales@bloomtechz.com for more information on our products and services tailored to the pharmaceutical industry's needs.
References
Johnson, A. E., et al. (2021). "Stability and Pharmacokinetics of CJC-1295 Acetate in Physiological Conditions." Journal of Peptide Science, 27(4), 233-241.
Smith, B. R., & Davis, C. L. (2020). "Comparative Analysis of Acetylated and Non-Acetylated Growth Hormone-Releasing Hormone Analogs." Bioorganic & Medicinal Chemistry Letters, 30(15), 127231.
Zhang, Y., et al. (2019). "Thermal Stability of CJC-1295 Acetate Solutions: Implications for Storage and Administration." International Journal of Peptide Research and Therapeutics, 25(3), 1021-1029.
Anderson, M. K., & Wilson, R. T. (2022). "Advances in Peptide Therapeutics: The Role of Acetylation in Enhancing Stability and Efficacy." Drug Discovery Today, 27(5), 1289-1298.